Lucia Celona Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lucia Celona APLS stock SEC Form 4 insiders trading

Lucia has made over 1 trades of the Apellis Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Lucia exercised 3,744 units of APLS stock worth $143,620 on 14 February 2018.

The largest trade Lucia's ever made was exercising 3,744 units of Apellis Pharmaceuticals Inc stock on 14 February 2018 worth over $143,620. On average, Lucia trades about 468 units every 0 days since 2017. As of 14 February 2018 Lucia still owns at least 22,780 units of Apellis Pharmaceuticals Inc stock.

You can see the complete history of Lucia Celona stock trades at the bottom of the page.

What's Lucia Celona's mailing address?

Lucia's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, WALTHAM, MA, 02451.

Insiders trading at Apellis Pharmaceuticals Inc

Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, and Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.

What does Apellis Pharmaceuticals Inc do?

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Apellis Pharmaceuticals Inc executives and stock owners

Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Cedric Francois,
  President, Chief Executive Officer, Co-Founder, Director
• Lukas Scheibler,
  Chief Innovation Officer
• Federico Grossi,
  Chief Medical Officer
• Thomas Lackner,
  Senior Vice President, Head of Europe
• Pascal Deschatelets,
  Co-Founder, Chief Operating Officer
• Timothy Sullivan,
  Chief Financial Officer, Treasurer
• Dr. Cedric Francois,
  Co-Founder, Pres, CEO & Director
• Timothy E. Sullivan,
  Chief Financial Officer
• Dr. Pascal Deschatelets Ph.D.,
  Co-Founder & Chief Scientific Officer
• Adam J. Townsend,
  Chief Commercial Officer
• Gerald Chan,
  Independent Chairman of the Board
• Stephanie O'Brien,
  Independent Director
• Alec Machiels,
  Independent Director
• A. Sinclair Dunlop,
  Independent Director
• Alec Machiels J.D., MBA,
  Co-Founder & Independent Director
• Sam Martin,
  IR Contact Officer
• Paul Fonteyne,
  Independent Director
• Adam Townsend,
  Chief Commercial Officer
• David Watson,
  General Counsel, Vice President of Corporate Development
• Nicole Perry,
  Vice President - Finance
• Victoria Brown,
  Senior Vice President, Program Team Lead – Systemic Chronic
• David O. Watson,
  Gen. Counsel
• Meredith Kaya,
  Sr. VP, Investor Relations & Strategic Fin.
• James G. Chopas CPA,
  VP, Corp. Controller & Chief Accounting Officer
• Dr. Lukas Scheibler M.D., Ph.D.,
  Chief Innovation Officer
• Karen Lewis,
  Chief People Officer
• Nur Nicholson,
  Chief Technical Operations Officer
• Dr. Federico Grossi M.D., Ph.D.,
  Co-Founder & Chief Medical Officer
• Nur Nicholson,
  Chief Technical Officer
• Karen Lewis,
  Chief People Officer
• Venture Investments Ltd Mor...,
  10% owner
• Lucia Celona,
  See Remarks
• Ahmad Sadr,
  See Remarks
• Jeffrey Eisele,
  Chief Development Officer
• Mark Jeffrey De Long,
  Chief Business & Strat Officer
• James George Chopas,
  VP/Chief Accounting Officer
• Caroline Baumal,
  Chief Medical Officer